Second Genome

Second Genome, a venture-backed Bay Area based life sciences company, is committed to improving the quality of human health through microbiome-based personalized medicine. Founded in 2009 by leading experts in microbial research, molecular diagnostics, and biotechnology R&D, Second Genome is using its proprietary Microbiome Signature Discovery platform to generate novel insights relating the microbiome with a wide range of human health disorders. Working with academic and commercial collaborators, Second Genome is developing novel diagnostic tools and therapies for unmet needs in gastrointestinal disorders. The company has established a pipeline of microbiome modulators that impact infection, inflammation, and metabolic diseases. Second Genome entered into the first ever big pharmaceutical partnership focused on microbiome drug discovery with Janssen Biotech, Inc. in June 2013 for new treatments for ulcerative colitis.
Company Growth (employees)
South San Francisco, US
Size (employees)
57 (est)+6%
Second Genome was founded in 2009 and is headquartered in South San Francisco, US

Key People/Management at Second Genome

Todd DeSantis

Todd DeSantis

Co-Founder & Head of Bioinformatics
Janet A. Warrington

Janet A. Warrington

Co-Founder & SVP, Platform Technologies
Peter S. DiStefano

Peter S. DiStefano

Sr VP Research & Development
Mohan Iyer

Mohan Iyer

SVP Corporate Development

Second Genome Office Locations

Second Genome has an office in South San Francisco
South San Francisco, US (HQ)
341 Allerton Ave
Show all (1)

Second Genome Financials and Metrics

Summary Metrics

Second Genome's latest funding round in July 2016 was reported to be $8.4 m. In total, Second Genome has raised $76.5 m

Second Genome's Web-traffic and Trends

Second Genome Online and Social Media Presence

Second Genome Company Life and Culture

You may also be interested in